Hoxworth Blood Center honored by City of Cincinnati leadership for 85 years of serving the greater Cincinnati community
Hoxworth Blood Center, University of Cincinnati was honored with a resolution by City of Cincinnati leadership at City Hall on January 31, 2024 for Hoxworth’s 85 years of dedicated service to the greater Cincinnati community.
Hoxworth Blood Center celebrated their 85th anniversary on December 10, 2023 and is currently the oldest operating blood center in the nation.
Hoxworth is the sole supplier of blood products to more than 30 hospitals and medical centers across 18 counties in Ohio, Kentucky, and Indiana.
Hoxworth Blood Center would like to thank City of Cincinnati leadership, including Mayor Aftab Pureval and Vice-Mayor Jan Michelle Lemon-Kearney, as well as blood recipient and Hoxworth advocate, Sister Keli, for spreading awareness on blood donation and continuously supporting Hoxworth's mission in Saving Lives Close to Home.
Related Stories
Taking a second look at surgery eligibility for patients with lung cancer who smoke
June 11, 2026
Researchers at the University of Cincinnati College of Medicine have found that patients who continue to smoke ahead of lung cancer surgery have a higher risk of pulmonary complications, but their short-term mortality rate is similar to patients who were able to stop smoking before surgery.. Their findings were published recently in the Journal of. American College of Surgeons
Patients with developmental disabilities may benefit with an integrated care model
June 9, 2026
Researchers from the University of Cincinnati and Ohio State University have found that adults with developmental disabilities who have integrated care were less likely to go to the emergency room or be hospitalized than others who were not. Their work was published in Disability and Health Journal.
UC physician-researcher's work yields landmark five-year data for Crohn's disease drug
June 8, 2026
The University of Cincinnati College of Medicine’s Anita Afzali, MD, leads a landmark study revealing five-year efficacy and safety data for a Crohn’s disease drug called guselkumab.